Artiva Biotherapeutics (ARTV) Competitors $2.44 +0.07 (+2.95%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.50 +0.06 (+2.25%) As of 05/2/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ARTV vs. CRVS, CADL, DSGN, CDTX, ENGN, RZLT, DRUG, HUMA, PLX, and KODShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Corvus Pharmaceuticals (CRVS), Candel Therapeutics (CADL), Design Therapeutics (DSGN), Cidara Therapeutics (CDTX), enGene (ENGN), Rezolute (RZLT), Bright Minds Biosciences (DRUG), Humacyte (HUMA), Protalix BioTherapeutics (PLX), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Corvus Pharmaceuticals Candel Therapeutics Design Therapeutics Cidara Therapeutics enGene Rezolute Bright Minds Biosciences Humacyte Protalix BioTherapeutics Kodiak Sciences Artiva Biotherapeutics (NASDAQ:ARTV) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings. Does the MarketBeat Community prefer ARTV or CRVS? Corvus Pharmaceuticals received 279 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 62.08% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArtiva BiotherapeuticsOutperform Votes14100.00% Underperform VotesNo VotesCorvus PharmaceuticalsOutperform Votes29362.08% Underperform Votes17937.92% Is ARTV or CRVS more profitable? Artiva Biotherapeutics' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A N/A N/A Corvus Pharmaceuticals N/A -70.71%-45.90% Do analysts rate ARTV or CRVS? Artiva Biotherapeutics presently has a consensus price target of $20.40, indicating a potential upside of 736.07%. Corvus Pharmaceuticals has a consensus price target of $15.67, indicating a potential upside of 332.78%. Given Artiva Biotherapeutics' higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals and insiders believe in ARTV or CRVS? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer ARTV or CRVS? In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 2 mentions for Corvus Pharmaceuticals and 1 mentions for Artiva Biotherapeutics. Corvus Pharmaceuticals' average media sentiment score of 1.17 beat Artiva Biotherapeutics' score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, ARTV or CRVS? Artiva Biotherapeutics has higher revenue and earnings than Corvus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$251K236.84N/AN/AN/ACorvus PharmaceuticalsN/AN/A-$27.03M-$0.97-3.73 SummaryCorvus Pharmaceuticals beats Artiva Biotherapeutics on 7 of the 13 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.45M$2.97B$5.55B$8.04BDividend YieldN/A1.87%5.09%4.22%P/E RatioN/A30.5222.6918.83Price / Sales236.84494.70404.28106.72Price / CashN/A168.6838.1834.62Price / BookN/A3.216.794.33Net IncomeN/A-$72.35M$3.22B$247.97M7 Day Performance-1.21%13.48%3.37%3.18%1 Month Performance-3.94%12.33%6.95%8.13%1 Year PerformanceN/A-23.51%16.13%5.01% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva BiotherapeuticsN/A$2.44+3.0%$20.40+736.1%N/A$59.45M$251,000.000.0081CRVSCorvus Pharmaceuticals2.4612 of 5 stars$3.50-3.6%$15.67+347.6%+109.2%$238.48MN/A-3.7630Upcoming EarningsCADLCandel Therapeutics2.2901 of 5 stars$4.97-0.2%$21.00+322.5%-37.4%$234.76M$120,000.00-2.8760Positive NewsGap UpDSGNDesign Therapeutics1.5181 of 5 stars$4.06+4.6%$8.00+97.0%+27.4%$230.46MN/A-4.7840Upcoming EarningsCDTXCidara Therapeutics4.3574 of 5 stars$21.03-2.4%$39.14+86.1%+71.1%$230.34M$1.28M-0.8290Analyst ForecastNews CoverageHigh Trading VolumeENGNenGene3.4384 of 5 stars$3.99+2.6%$23.29+483.6%-75.1%$229.40MN/A-6.8831Analyst ForecastShort Interest ↑RZLTRezolute2.7249 of 5 stars$3.76-2.3%$26.43+602.9%+34.7%$227.61MN/A-3.0840Short Interest ↑DRUGBright Minds Biosciences3.3654 of 5 stars$32.18-1.6%$84.33+162.1%+2,975.8%$226.68MN/A-189.28N/ANews CoverageHUMAHumacyte2.8429 of 5 stars$1.46+1.4%$13.71+839.3%-70.2%$226.47M$1.57M-1.09150Upcoming EarningsPLXProtalix BioTherapeutics2.8224 of 5 stars$2.85flat$15.00+426.3%+158.6%$222.39M$53.40M-21.92200Analyst RevisionNews CoveragePositive NewsKODKodiak Sciences4.0427 of 5 stars$4.21+2.4%$9.00+113.8%+29.7%$222.07MN/A-1.1590News CoveragePositive News Related Companies and Tools Related Companies CRVS Alternatives CADL Alternatives DSGN Alternatives CDTX Alternatives ENGN Alternatives RZLT Alternatives DRUG Alternatives HUMA Alternatives PLX Alternatives KOD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and s...Premier Gold Co | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARTV Stock Free ARTV Stock Alerts